Attention Deficit Disorder With Hyperactivity Clinical Trial
Official title:
Marijuana-Abusing Attention Deficit Hyperactivity Disorder (ADHD) Teens: Atomoxetine Treatment
Attention Deficit Hyperactivity Disorder (ADHD) is common among adolescents seeking treatment for marijuana dependence. The purpose of this study is to determine the use of atomoxetine in treating adolescents who abuse marijuana and have ADHD. In addition, this study will assess whether atomoxetine reduces ADHD symptoms as compared to a placebo. Finally, the study will determine whether atomoxetine improves treatment retention and progress in adolescents with ADHD and marijuana dependence.
Attention Deficit Hyperactivity Disorder (ADHD) is common among adolescents seeking treatment
for marijuana dependence. Therefore, it is important to develop treatments targeting
adolescents diagnosed with both ADHD and marijuana dependence. Atomoxetine is currently used
to treat individuals diagnosed with ADHD. The purpose of this study is to determine the
feasibility of administering atomoxetine in a therapeutic setting to adolescents who abuse
marijuana and have ADHD. In addition, this study will assess whether atomoxetine reduces ADHD
symptoms. Finally, this study will determine whether atomoxetine improves treatment retention
and progress in adolescents with ADHD and marijuana dependence.
Participants in this double-blind study will be randomly assigned to receive either
atomoxetine or placebo. Study visits will occur 2 times each week for the duration of the
12-week trial. At each study visit, vital signs and medication side effects will be assessed.
In addition, psychiatric ratings measurements will be evaluated. Participants will also
complete self reports in order to track ADHD-related symptoms. Starting at the Week 2 study
visit, all participants will receive psychotherapy sessions. This will involve
cognitive-behavioral therapy/relapse prevention treatment that has been designed specifically
for ADHD adolescents. The aim of the cognitive skills training will be to assist the
participants in developing the skills necessary to manage their drug use as well as the
symptoms they experience related to ADHD. At Month 6, a follow-up visit will occur, at which
time participants urine toxicology tests will be completed to determine if participants have
been using marijuana or any other substances of abuse. In addition, at the Month 6 follow-up
visit, participants will complete psychiatric ratings, self reports, and will meet with a
physician to assess ADHD-related symptoms.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00202605 -
Safety and Efficacy of SPD465 in Adults With ADHD
|
Phase 2 | |
| Not yet recruiting |
NCT02677519 -
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
|
Phase 4 | |
| Completed |
NCT02730572 -
Concerta (Methylphenidate) -To-Generic Switch Study
|
N/A | |
| Completed |
NCT01681082 -
Psychological Effects of Tai Chi Training
|
N/A | |
| Active, not recruiting |
NCT01330693 -
Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy
|
Phase 3 | |
| Completed |
NCT00830700 -
Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study
|
N/A | |
| Completed |
NCT01012622 -
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
|
Phase 4 | |
| Completed |
NCT00626236 -
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
|
Phase 2 | |
| Completed |
NCT00598182 -
Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study
|
N/A | |
| Completed |
NCT00381407 -
Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder
|
N/A | |
| Completed |
NCT00178503 -
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
|
Phase 2/Phase 3 | |
| Completed |
NCT00247572 -
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
|
Phase 2 | |
| Completed |
NCT00218322 -
Effectiveness of ATMX in Treating Adolescents With ADHD and SUD
|
Phase 4 | |
| Completed |
NCT00118911 -
Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder
|
N/A | |
| Completed |
NCT00557011 -
NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD
|
Phase 2 | |
| Completed |
NCT00071656 -
Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I
|
N/A | |
| Active, not recruiting |
NCT00057668 -
Preventing Behavior Problems in Children With ADHD
|
Phase 2 | |
| Completed |
NCT00050622 -
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
|
N/A | |
| Completed |
NCT00050050 -
Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder
|
Phase 1 | |
| Completed |
NCT00031395 -
Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children
|
Phase 3 |